Vector text: ERIC

Patent Reform

Why Employers Care

Employers have a vested interest in patent reform. When patents on brand-name pharmaceuticals expire, the introduction of biosimilars and generics typically leads to lower drug prices, which can reduce overall health care expenses for both the company and its employees. Reforming patent laws to facilitate faster and more predictable entry of these alternatives into the market helps ensure that employees have access to more generics and biosimilars. This not only supports better health outcomes, but also aligns with employers’ goals of managing health care costs and providing valuable benefits to their workforce. In essence, patent reform in this area is crucial for maintaining an economically sustainable benefits program while supporting the health and well-being of employees.

Patent Reform Overview One-Pager

Needed Patent Reforms Will Lower Drug Costs One-Pager

Stop Drug Manufacturers From Abusing the Patent System and Engaging In Anti-Competitive Practices One-Pager

Needed Patent Reforms Will Lower Drug Costs

Medication Affordability and Patent Integrity Act (S. 2780 and H.R. H.R. 5429)

 Interagency Patent Coordination and Improvement Act of 2023 (S. 79 and H.R. 1717)

Preserve Access to Affordable Generics and Biosimilars Act (S. 142)

Stop STALLING Act (S. 148)

Affordable Prescriptions for Patients Act of 2023 (S. 150 and H.R. 9070)

Stop Drug Manufacturers From Abusing the Patent System and Engaging In AntiCompetitive Practices

A Bill to Address Patent Thickets (S. 3583 and H.R. 6986)

Prescription Pricing for the People Act of 2023 (S. 113)

Other Resources

An Update on Patents – How Reforms Could Impact Drug Costs For Plans and Their Beneficiaries (06.24.24 Webinar)

PPT Presentation from 06.24.24 Patent Webinar